Welcome to our dedicated page for Hims & Hers Health news (Ticker: HIMS), a resource for investors and traders seeking the latest updates and insights on Hims & Hers Health stock.
Hims & Hers Health, Inc. reports news about its consumer telehealth platform, which connects customers with providers and offers treatment options across areas such as sexual health, hair loss, skin care, mental health and weight loss. Company updates commonly cover prescription access, FDA-approved GLP-1 weight loss medications, platform memberships, subscriber benefits and health-and-wellness partner programs.
Recurring developments also include operating and financial results, conference participation, board and executive appointments, shareholder voting matters, governance updates and clinical or regulatory disclosures tied to products available through the Hims and Hers platform.
Hims & Hers Health, Inc. has launched Hard Mints, a prescription chewable tablet designed for erectile dysfunction. These mint-flavored tablets utilize active ingredients found in popular medications like Cialis© and Viagra©, providing a personalized treatment option. Priced from $30 per month, Hard Mints come in various dosages, allowing for tailored healthcare solutions. The introduction of this product is part of Hims & Hers' commitment to innovating personalized health treatments, aiming to enhance patient confidence and improve access to necessary medications.
Hims & Hers Health, Inc. (NYSE: HIMS) will report its fourth quarter and full year 2022 financial results on February 27, 2023, after market close. A conference call is scheduled for 5:00 p.m. ET that same day to discuss the results. Participants can join by dialing (888) 510-2630 for U.S. callers or (646) 960-0137 for international attendees, using conference ID 1704296. The call will also be available via a live audio webcast, which will be archived for one year on the company's investor relations website.
Additionally, Hims & Hers management will participate in several upcoming investor conferences in March 2023, including events hosted by Citi, JMP Securities, and KeyBanc.
Hims & Hers Health, Inc. (NYSE: HIMS) has launched a new line of volumizing shampoos and conditioners, formulated with Biovolume 128™ to enhance hair volume. These vegan and cruelty-free products target individuals with fine or limp hair. Notably, the new items include Hims Max Volume Shampoo and Conditioner, and Hers Full Volume Shampoo and Conditioner, featuring ingredients like Biotin and Hydrolyzed Rice Protein. Available for purchase at ForHims.com, ForHers.com, and retailers like Walgreens, this expansion adds to the company's existing hair care offerings. Hims & Hers aims to provide personalized health solutions for customers.
Hims & Hers Health announces the return of Dr. Pat Carroll as Chief Medical Officer, aimed at enhancing clinical operations and patient care. Under his leadership, the company has reported unprecedented growth, nearing one million subscriptions and achieving a 95% year-over-year revenue increase to $144.8 million. Dr. Carroll's reappointment follows strong quarterly earnings and reflects the company's commitment to innovative, personalized healthcare solutions.
Hims & Hers Health, Inc. (NYSE: HIMS) appointed Dr. Scott Knoer as its first Chief Pharmacy & Innovation Officer, focusing on pharmacy strategy and innovation. With over two decades of experience, Knoer previously served as the Chief Pharmacy Officer at Cleveland Clinic and CEO of the American Pharmacists Association. Hims & Hers reported strong Q3 2022 results with a 95% revenue increase to $144.8 million and 170,000 new subscriptions, bringing total subscriptions to 991,000. The company is expanding its pharmacy operations with new facilities in Ohio and Arizona.
Hims & Hers Health, Inc. has partnered with ChristianaCare to enhance healthcare access, expanding its network to 10 states and Washington D.C. This collaboration will facilitate patient referrals for complex conditions, integrating ChristianaCare's Center for Virtual Health with Hims & Hers' platform. This move aligns with Hims & Hers' mission of providing high-quality, affordable care, benefiting consumers in Delaware, Maryland, New Jersey, and Pennsylvania. The partnership enhances service offerings, making healthcare more convenient and accessible.
Hims & Hers Health reported a strong Q3 2022 with a revenue of $144.8 million, up 95% year-over-year. The company gained over 170,000 net new subscriptions, totaling 991,000 subscriptions, representing an 80% increase year-over-year. Hims & Hers raised its 2022 revenue guidance to $519-$522 million and expects Adjusted EBITDA of $(20) million to $(18) million. Despite a net loss of $(18.8) million, the company aims for Adjusted EBITDA profitability in Q4 2022, citing operational leverage and consumer adoption.
Hims & Hers Health, Inc. (NYSE: HIMS) will report its third quarter 2022 financial results after the market closes on November 7, 2022. A conference call to discuss the results will be held at 5:00 p.m. ET, accessible via U.S. dialing at (888) 510-2630 and internationally at (646) 960-0137, with conference ID 1704296. Hims & Hers is a consumer-first health platform offering treatments for various conditions, connecting patients with healthcare professionals for prescription fulfillment through a subscription model.
Hims & Hers Health, Inc. (NYSE: HIMS) has appointed Brian O’Shaughnessy as Chief Communications Officer and Josh Krueger as VP of Fulfillment Operations. O’Shaughnessy brings over two decades of experience from Google and Skype, where he led notable product communications. Krueger, formerly at Walmart and Amazon, has significant expertise in fulfillment operations. These hires aim to enhance Hims & Hers’ growth and improve customer experiences, following strong financial results with over $100 million in revenue and 100,000 new subscribers in Q2 2022.
Summary not available.